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Four of 391 Ni-Vanuatu women were infected with vari-
ants of human T-cell leukemia virus type 1 (HTLV-1)
Melanesian subtype C. These strains had env nucleotide
sequences ≈99% similar to each other and diverging from
the main molecular subtypes of HTLV-1 by 6% to 9%.
These strains were likely introduced during ancient human
population movements in Melanesia.
H
uman T-cell leukemia virus type 1 (HTLV-1), a
human oncoretrovirus, is the etiologic agent of adult
T-cell leukemia and of tropical spastic paraparesis/HTLV-
1–associated myelopathy. Molecular epidemiologic stud-
ies have shown HTLV-1 proviruses to be remarkably stable
genetically. The low levels of genetic drift in this virus
have been used as a means for monitoring viral transmis-
sion and the movement of ancient human populations
(1,2). The few nucleotide substitutions observed in HTLV-
1 strains are specific to the geographic origin of the patient
and are unrelated to viral pathology (1,2). Four major geo-
graphic HTLV-1 subtypes have been described: subtype A,
cosmopolitan (1,2); subtype B, central African; subtype C,
Melanesian (3–6); and subtype D, present in central Africa,
mainly in pygmies. 
Previous reports have indicated that HTLV-1 is endem-
ic in some remote or ancient populations in Melanesia
(3–14). These populations include a small number of tribes
from Papua New Guinea (especially the Hagahai people)
(5) and some inhabitants of the Solomon Islands (7).
Evidence of HTLV-1 infection has also been found in some
aboriginal groups from Australia (8). Rare cases of adult T-
cell leukemia and tropical spastic paraparesis/HTLV-
1–associated myelopathy have also been described in these
populations (9).
Genetic characterization of the few available
Melanesian HTLV-1 strains has indicated that these HTLV-
1 strains are the most divergent, constituting molecular
subtype C (also called Melanesian subtype [3,4,6,10]) in
phylogenetic analyses. The discovery of such divergent
variants has increased our understanding of the migration
of HTLV-1–infected populations throughout the Pacific
region. Furthermore, 1 of the calibration methods fre-
quently used, in phylogenetic analyses, to estimate a time
scale for the evolution of HTLV and simian T-cell
leukemia virus (STLV) appears to coincide with the
first human migrations to Melanesia and Australia
40,000–60,000 years ago (2).
We carried out a large serologic and molecular study to
determine the prevalence of HTLV-1 and associated dis-
eases in the Vanuatu Archipelago. Vanuatu, formerly
known as the New Hebrides, is a Y-shaped archipelago
made up of ≈80 islands. It is located in Melanesia, in the
South Pacific region, northeast of Australia and south of
the Solomon Islands. Vanuatu has a population of
≈200,000 inhabitants, most of whom (95%) are of
Melanesian origin and are known as the Ni-Vanuatu. 
Very few seroepidemiologic studies on HTLV-1 in
Vanuatu have been carried out, and these studies examined
mostly small populations more than a decade ago and were
not based on stringent serologic criteria (11–14). No
molecular characterization data are available for HTLV-1
from this area. The main goals of this study were to evalu-
ate the situation concerning HTLV-1 infection in a remote
Ni-Vanuatu population by using stringent serologic criteria
for Western blotting and molecular characterization of the
viruses.
The Study
In February 2002, we recruited 391 women during a
clinical survey for sexually transmitted diseases in various
remote rural communities of western Ambae Island in the
Penama Province of the Vanuatu Archipelago. Ambae
Island, also known as Aoba, has a population of ≈9,500.
The women participating in this survey were offered a
complete clinical examination, with Papanicolaou test
analysis for all women >25 years of age. For each partici-
pant, we obtained plasma and buffy coats from 5 mL of
blood obtained by venipuncture. The blood samples were
rapidly transferred to Institut Pasteur de Nouvelle-
Calédonie, where plasma and buffy coats were isolated,
frozen, and stored (at –80°C) until HTLV screening.
Informed consent was obtained from each woman partici-
pating in the field survey. This study was approved by the
Ministry of Health of the Republic of Vanuatu and was
supported by the Vanuatu Family Health Association, a
local nongovernmental organization. Samples were taken
from 391 women (mean age 36 years, range 16–82 years)
with the following stratification by age: 11.2% from
women 15–24 years of age, 28.4% from women 25–34
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Port-Vila, Vanuatuyears of age, 31.2% from women 35–44 years of age,
17.4% from women 45–54 years of age, and 11.8% from
women >55 years of age. 
Plasma HTLV-1 antibodies were detected by enzyme-
linked immunosorbent assay (ELISA) (HTLV-I+II, Abbott-
Murex, Kent, United Kingdom) with Western blot
(HTLV-I/II Blot 2.4, Diagnostic Biotechnology, Singapore)
used for confirmation. On Western blot, plasma samples
were considered HTLV-1–positive if they reacted to the 2
Gag proteins (p19 and p24) and both env-encoded glyco-
proteins: the HTLV-1–specific recombinant gp46-I peptide
(MTA-1) and the specific HTLV-1/HTLV-2 recombinant
GD 21 protein. Plasma samples were considered negative
when no band were shown and indeterminate when partial-
ly reactive (15,16).
Forty-nine of the 391 plasma samples studied tested
positive or borderline by ELISA, and 4 of these samples
displayed full reactivity on Western blot (Figure 1). One
sample also displayed a typical HTLV gag-indeterminate
profile (16), and 6 displayed weak reactivity (19 or GD 21
bands). The 4 plasma samples testing positive by Western
blot had higher immunofluorescence assay titers on MT2
(HTLV-1) cells than on C19 (HTLV-2) cells and high par-
ticle agglutination titers (Table 1). We carried out a second
serologic survey on 64 members of the families of the 4
women seropositive for HTLV-1. This survey identified 2
more infected women; 1 was the mother of an index
patient, and the other was the sister-in-law of another index
patient (Table 1). These results confirm the circulation of
HTLV-1 in this population.
High molecular-weight DNA was extracted from buffy
coats from the 4 HTLV-1–seropositive women, 5 HTLV-
1–seronegative persons, and 6 others with indeterminate
Western blot results, by using the QIAamp DNA Blood
Mini Kit (Qiagen GmbH, Hilden, Germany). The 15 DNA
samples studied were subjected to polymerase chain reac-
tion with primers specific for the human β-globin gene to
check that cellular DNA was amplifiable for all samples
(17). We then subjected DNA samples to 2 series of poly-
merase chain reaction to obtain the complete long terminal
repeat (LTR) (755 bp) and a 522-bp region of the env gene
as previously described (18). Fragments of the appropriate
size were amplified for the 4 HTLV-1–seropositive
women, whereas the other 11 samples yielded negative
results. The amplified products were cloned and
sequenced, and phylogenetic studies were performed as
previously described (18). Both the complete LTR and the
522-bp  env fragment were obtained for the 4 HTLV-
1–seropositive women.
Conclusions
The gp21 gene sequences of the 4 HTLV-1 strains
involved were almost identical (99.6%–99.8 % nucleotide
similarity) and were very similar to those of Melanesian
strains. These strains were closely related (99.4%) to
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Figure 1. Representative seroreactivity pattern on Western blot
that contains a recombinant GD 21 (common to human T-cell
leukemia virus type 1 [HTLV-1] and HTLV-2) and 2 synthetic pep-
tides specific for HTLV-1 (MTA-1) and HTLV-2 (K55). Lane 1,
HTLV-1-positive control; lane 2, HTLV-2-positive control; lane 3,
HTLV-1/2 negative control; lane 4-9, 6 plasma samples from the
HTLV-1-positive women of Ambae Island displaying strong reactiv-
ity to GD 21 (faint band for VAN 251), to p19 and p24 (faint band
for VAN 54), p26, p28, p32, p36 (faint bands for VAN 54 and
AWM), and to MTA-1.certain strains from Solomon Islanders (Mel 4, 8) but were
only 97.1%–98.3% similar to strains from Papua New
Guinea residents (Mel 2, 7) and from Australian aborigines
(MSHR-1), respectively. Finally, the sequences of these
new strains diverged from those of HTLV-1 strains from
the 3 other main molecular subtypes (A, B, D) by 6%
to 9%.
The 4 new HTLV-1 LTR sequences were also very
closely related (98 %–100% nucleotide similarity). They
displayed 2% nucleotide divergence from Mel 5 (from a
Solomon Islander), the only available LTR from all the
HTLV-1 subtype C strains. However, they also displayed
up to 11% nucleotide divergence from HTLV-1 strains
from other molecular subtypes.
Phylogenetic analyses were performed on all the avail-
able env and LTR HTLV-1 sequences from Melanesia, and
on several representatives of HTLV-1 and STLV-1 strains
from the various subtypes/subgroups as described (18), by
the neighbor-joining (NJ) method. Similar tree topologies
were obtained for both genomic regions (Figure 2 and
Appendix Figure, which is available online at http://www.
cdc.gov/ncidod/EID/vol11no05/04-1015_app.htm).
Analyses of these trees confirmed that the 4 novel Vanuatu
HTLV-1 strains were closely related to all available HTLV-
1 subtype C strains (Table 2). Indeed, in the env analysis,
which included 71 HTLV-1 strains (including 12
Melanesian strains and 1 from an Australian aborigine,
Table 2) and 55 STLV-1 strains, the 4 new HTLV-1 strains
clustered with subtype C (Figure 2). This subtype only
includes strains from Australia, Papua New Guinea, the
Solomon Islands, and Vanuatu. Within this clade are at
least 2 subgroups, strongly supported phylogenetically: 1
comprises the Vanuatu strains and most of the strains from
the Solomon Islands (bootstrap values of 88%), and the
other comprises the 3 isolates from Papua New Guinea (the
Hagahai population), with a bootstrap value of 100%. Two
other unique and divergent strains, the only strain available
from an Australian aborigine (MSHR-1) and the other from
a Solomon Islander (Mel-12), may represent prototypes of
2 other clades within the Melanesian subtype C.
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Figure 2. Unrooted phylogenetic tree generated by the neighbor-joining method by using the 522-bp fragment of the env gene. Distance
matrices were generated with the DNADIST program, using the Kimura 2-parameter method and 5.65 as the transition/transversion ratio.
Bootstrap analysis was carried out with 1,000 datasets. The values on the branches indicate frequencies of occurrence for 1,000 trees.
The 4 new human T-cell leukemia virus type 1 (HTLV-1) sequences (VAN 54, VAN 136, VAN 251, VAN 335; GenBank accession nos.
AY549879, AY549880, AY549881, AY549882) were analyzed with 126 HTLV-1/simian T-cell leukemia virus type 1 (STLV-1) sequences
available from the GenBank database. The branch lengths are proportional to the evolutionary distance between the taxa. In conclusion, we report, for the first time, the presence
of HTLV-1 infection in a Ni-Vanuatu population living in
remote villages. We also demonstrate that the viruses
infecting these Ni-Vanuatu persons are novel HTLV-1
molecular variants belonging to the Melanesian divergent
C subtype. This finding suggests that these viruses were
introduced into Vanuatu by ancient migrations of
Melanesian populations. The first people to reach Santa
Cruz, Banks, Vanuatu, and the Loyalties Islands ≈3,600
years ago seem to have been Austronesian speakers (19).
Epidemiologic and clinical surveys are under way in this
area to determine the extent of such retroviral infection and
associated neurologic and hematologic diseases. In addi-
tion, studies of viral and mitochondrial/nuclear DNA are
being conducted and should provide insight into the migra-
tions of the first settlers and the origin, evolution, and
modes of dissemination of such retroviruses. 
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